INTRODUCTION
Retroperitoneal sarcomas (RPS) are rare tumors, with an expected incidence of .5-1 new case/100,000 inhabitants per year. 1 Surgery is the mainstay of curative therapy and local control is critical for cure. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Overall local/abdominal recurrence is common (&50 % at 5 years overall) following resection of primary retroperitoneal sarcoma (RPS). [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] A high proportion of recurrences occur late (after 5 years), mandating ongoing follow-up. [13] [14] [15] Different histologic subtypes have different patterns and timing of recurrence following resection of primary RPS. 2, 3, 16 The distribution of histological subtypes in recurrent RPS is distinct from that of primary RPS. 2, 3, 16, 17 Local recurrence, and/or its treatment, is the most common cause of death from RPS. In general, recurrent RPS is associated with a worse prognosis than primary RPS. 3, 11, [18] [19] [20] A trans-Atlantic RPS working group (TARPSWG) was established in 2013. Included in the working group were North-American and European centers who accepted the invitation. The group has published a consensus approach to primary RPS and a large, multicenter, retrospective case series analysis on primary RPS. 2, 13 As a follow-up of the consensus approach to primary RPS, the group expanded substantially, including several more European and North American centers, and developed this consensus on recurrent RPS. A larger, multicenter, retrospective review on recurrent RPS is presently ongoing and a prospective registry, just finalized, is starting soon.
METHODS
An extensive literature search of published evidence was made and-given the paucity of available data-the TARPSWG developed guidelines on recurrent RPS mainly based on expert agreements. The working group initially met during the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, IL. A document was drafted and circulated in the following months. The group then formally convened during the 2015 Connective Tissue Oncology Society Annual Meeting in Salt-Lake City, Utah. The document was finally approved at a meeting during the 2016 Society of Surgical Oncology Annual Meeting in Boston, Massachusetts. All group members reviewed and agreed to the present version of the recommendations.
The following statements apply to recurrent RPS that is nonvisceral in origin.
• Included are ''usual'' recurrent retroperitoneal sarcoma (liposarcoma, leiomyosarcoma, solitary fibrous tumor, malignant peripheral nerve sheath tumors, synovial sarcoma, etc.) • Included are sarcomas of major veins (inferior vena cava, renal vein, ovarian/testicular vein), undifferentiated pleomorphic sarcoma of psoas, ureteric leiomyosarcoma (LMS).
• Excluded are benign entities, such as desmoids and angiomyolipoma.
• Excluded are gastrointestinal stromal tumors, visceral sarcomas, such as those arising from the gut or its mesentery, uterine LMS, prostatic sarcoma, paratesticular/spermatic cord sarcoma.
• Excluded are Ewing sarcoma, alveolar/embryonal rhabdomyosarcoma, sarcoma arising from teratoma, carcinosarcoma, sarcomatoid carcinoma, clear cell sarcoma, radiation-induced sarcoma.
• Excluded are paraganglioma and malignant pheochromocytoma.
RESULTS
Principles of recommended practice from diagnosis to follow-up are summarized in 42 statements. Each statement has been attributed a level of evidence according to the scale reported in Table 1 . 21 1. Prior to undertaking a management decision, patients with recurrent RPS should be presented at a MultiDisciplinary Case Conference with participation by surgical oncologists, medical oncologists, radiation oncologists, pathologists and radiologists with expertise in sarcoma (VA).
Pretreatment Assessment
Imaging 2. All relevant imaging studies performed prior to resection of the primary RPS should be obtained and reviewed, as should all subsequent imaging studies, in particular the initial postoperative baseline imaging to determine whether prior resection was in fact grossly incomplete (R2) (VA). 3. Current extent of local and distant disease should be determined using oral and intravenous (IV) contrast enhanced computed tomography of the chest, abdomen and pelvis (CT-CAP) (IVA). [22] [23] [24] 4. Current imaging should be compared to all prior imaging to ascertain the extent and progression of recurrent disease, with attention to pattern of relapse (locoregional vs. peritoneal) and rate of progression (IVB). 25 5. The risk of invasion into adjacent organ(s)/critical structure(s) with further progression should be evaluated, and taken into account when deciding on the best management approach (VB). 6. MRI may be a useful ancillary modality in selected cases to define extent of adjacent organ/structure involvement that is not clear on CT but is not required in most cases (IVB). 26 MRI may be helpful in operative planning for pelvic tumors or tumors that abut/involve bone or psoas or oblique muscles or vertebral foramen. 23 MRI also is an option in patients with IV contrast allergy or other serious contraindication to CT (IVB). 23 7. PET scan is rarely indicated; it may be indicated if the extent of active abdominal disease is difficult to evaluate and/or there is uncertainty about different growth characteristics in multifocal lesions that would alter management (IVB). An example is shown in Fig. 1 .
Histopathology of the primary tumor should be reviewed by a pathologist specialized in the evaluation of soft tissue tumors; molecular subtyping should be performed where appropriate (e.g., Mdm2 in lipomatous tumors) (VA). 10. Percutaneous core biopsy confirmation of recurrence is often useful, for a number of reasons: 1) to provide a definitive diagnosis, because a variety of other entities can be mistaken for recurrence of the original primary RPS, for example desmoid fibromatosis ( Fig. 2) , radiation-associated osteosarcoma, or angiosarcoma in the bed of original LPS; 2) to guide selection of preoperative therapies, including potential targeted therapies; 3) as part of a translational research program or clinical trial; 4) because resection often is challenging and may be morbid and should not be undertaken without due cause (VB).
Patient Evaluation
11. The patient's symptoms, and pace of symptom progression, should be noted The patient's current performance status should be recorded. Physical examination should include notation of previous incisions, and the relationship of new tumor mass(es) to previous incisions, including port sites (VB). 12. Renal function and nutritional status must be assessed (VB). 17. Details of any previously administered radiotherapy or systemic therapy should be reviewed (VA).
Patient Selection for Resection of Recurrence
18. While complete gross resection can be viewed as the only curative-intent option in patients with recurrent RPS, the chance of long term disease-free survival is limited and this must be recognized in multidisciplinary evaluation and planning of management for the individual patient (IVA).
3,29
The decision to pursue curative resection is multifactorial and often nuanced. A nomogram to assist in this decision is presently lacking, the available ones mainly built to predict the risk of primary disease. 30 Variables to be considered are discussed below.
Abdominal Recurrence
19. In the case of isolated locoregional recurrence, especially if the previous resection was incomplete, the goal of resection should be curative, and the extent of resection should be as required to achieve complete gross resection (IVB). [31] [32] [33] [34] 19.1. For local recurrence of WD-LPS within the field of previous resection(s), the surgeon may rationally wait for an increase in tumor size in order to space out the interval between operations (IVB). 35 20. Multifocal intra-abdominal disease is difficult to resect completely, will almost certainly recur again, and carries a poor prognosis particularly with resection alone. The prognosis following resection worsens with increasing number of intraperitoneal deposits. 34 Any resection should be with the goal of avoiding complications of progression and preserving function (i.e., limited resection) or with palliative intent as discussed below. Because the oncologic benefit of surgery is likely to be limited and the risk of morbidity may be substantial, a very careful approach to patient selection for surgical intervention is required (IVA). generally not appropriate; resection should be with the goals of avoiding complications of progression and preserving function (limited resection); a possible exception is a previous flank/lumbar approach, where piecemeal resection may not have been associated with peritoneal contamination (IVB). In general, with each serial resection, the oncologic outcome deteriorates, and the chance of mortality and serious morbidity are magnified (IVB). 32 The often indolent course of recurrent disease (particularly LPS), even in the presence of a bulky mass, should be considered when major morbidity is expected following resection and the patient is asymptomatic (IVB). 35 
Distant Recurrence
26. Selected patients with limited oligo-metastatic recurrence of RPS may have prolonged survival following metastasectomy (e.g., LMS) (IVB). 37 27. In general, synchronous abdominal and distant recurrence should not be resected, and the patient should be considered for systemic therapy as part of a multimodality approach based on tumor histology/molecular subtyping (IVB). 37 
Preoperative Therapy
28. For patients being considered for resection of recurrent RPS, neoadjuvant therapy should be considered (VB).
28.1. Cytotoxic and/or targeted systemic therapies may be of benefit in downsizing recurrent disease to improve resectability, especially in the case of LMS, DD-LPS, UPS, SFT, and synovial sarcoma, and also may facilitate assessment of tumor biology/prognosis, especially when a high grade RPS has recurred after a short disease-free interval, and when resection of locally recurrent disease is anticipated to be morbid (VB). 28.2. Preoperative XRT should be considered, particularly if no previous XRT has been administered and the recurrence is isolated, although its value in improving disease control has not been studied, and toxicity may be magnified in the setting of prior resection (VB).
29. Response to treatment varies by histological subtype of RPS and the management plan should be developed in recognition of this and in conjunction with a multidisciplinary care team (VB).
Preoperative treatment of recurrent RPS should ideally be given within the context of a clinical trial. 31. The use of intraoperative frozen sections on marginal tissues as a guide to extent of resection is generally not advised. Frozen-section analysis of soft-tissue tumors is frequently problematic, and particularly so in the setting of reoperative surgery and previous receipt of adjuvant therapies (VA). Result of frozen-section analysis may be misleading. In some specific scenarios, such as LMS of a major vein, frozen-section analysis of a vascular margin may be useful if additional tissue at the relevant site can be removed (VB). 32. Technical and non-technical peri-operative considerations are as enunciated in the TARPSWG consensus statement on management of primary RPS (IVA).
13,38
Postoperative Systemic Therapy and Other Locoregional Therapies 33. There is no proven role for prophylactic systemic therapy after complete resection of recurrent RPS (IVC). 39, 40 34. There is no proven role for brachytherapy or postoperative XRT after resection of recurrent RPS, and each may lead to increased morbidity (IVE). 41, 42 34.1 IORT may be considered following resection of recurrent RPS, although the evidence is weak (IVD). 43 35. There is no proven role for intraperitoneal chemotherapy, but it could be considered for highly selected patients and histologies (IVD). [44] [45] [46] [47] [48] [49] Ideally intraperitoneal therapy for these specific histologies should be administered within the context of a clinical trial. For usual histological subtypes, the results of debulking surgery and intraperitoneal chemotherapy for multifocal intraperitoneal sarcoma have been uniformly poor with prohibitive morbidity. 36. There is no proven role for regional hyperthermia (IIID). 50 37. After resection of recurrent RPS, patients should be followed with regular cross-sectional imaging, given the high risk for further relapse (IVB). 39. Patients should be considered for palliative procedures as symptoms arise. Early referral for symptom management is desirable (VA). 40. XRT may be of palliative benefit, in particular with pain control related to nerve compression or infiltration (VB). 41. In select patients, survival with recurrent RPS may be prolonged (e.g., WD-LPS). The potential to live many years despite the ongoing presence of recurrent disease should be recognized and adequately communicated to the patient (VB). 42. R2 resection may be indicated for symptom control in highly selected patients, particularly if WD-LPS; in contrast R2 resection for more aggressive histologies may increase the risk for peritoneal dissemination/ sarcomatosis (VB).
CONCLUSIONS
The available evidence on the approach to recurrent RPS is clearly limited. This is the largest consensus document on this topic and follows the one on primary RPS. An effort to merge and formally report the retrospective experience of the participating institutions, which backs its development, is presently ongoing. The two documents will help to harmonize the approach to this difficult disease. Another major effort to enter all eligible patients onto an international collaborative prospective registry is being finalized and will be active soon. We anticipate that this registry will be the basis of much further understanding of this difficult disease and will serve as a platform for collaborative translational research.
Bio-banking of fresh/frozen tissue should be encouraged to facilitate future research. Evaluations of long-term function and quality-of-life following therapy for recurrent RPS are lacking. Ideally quality-of-life should be assessed preoperatively, as well as postoperatively. The poor prognosis of recurrent RPS highlights the importance of optimal management of primary RPS. 13 
